“Reporting Information Regarding Falsification of Data” Proposed Rule

First Page		Document Content
Research Drug discovery Pharmacokinetics Pharmaceutical industry Clinical trial Dose Nonclinical studies Bioequivalence Bioavailability Pharmacology Pharmaceutical sciences Clinical research		“Reporting Information Regarding Falsification of Data” Proposed Rule Add to Reading List Source URL: www.fda.gov Download Document from Source Website File Size: 122,96 KB Share Document on Facebook

	Pediatric Product Development: Nonclinical Studies Melissa S Tassinari PhD DABT FDA/ CDER/ OND/ PMHS Principles of pediatric drug development DocID: HVPX - View Document
	Guidance for Industry Coronary Drug-Eluting Stents - Nonclinical and Clinical Studies DocID: H9Oa - View Document
	CERE-110 Nonclinical Studies RAC Meeting March 11, 2004 Raymond T. Bartus, Ph.D. Vice President, Research & Development DocID: Fi9Q - View Document
	Quark Clinical Experience with Synthetic siRNAs u Overview of Quark development programs u Summary of nonclinical and clinical experience in the eye following local (intravitreal) administration DocID: EdaL - View Document
	A Joint Meeting of the FDA Medical Imaging Drugs Advisory Committee and the Oncologic Drugs Advisory Committee May 3, 2013 Leukocyte Growth Factors (LGFs) as Treatments DocID: DNN3 - View Document